Explore the vast range of titles available.

We conducted an overview to assess immune adverse effects associated with the COVID-19 vaccine, guiding safer choices and providing evidence-based information to clinicians. Forty-three studies on adverse effects of vaccines were reviewed from PubMed, Embase, and Web of Science. Single-arm meta-analyses estimated summary effects, incidence, presentation, etc. An overview using single-arm meta-analysis and reported the findings following the guidelines outlined in the 'Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) specifically focusing on myocarditis and thrombosis. After screening 2,591 articles, 42 studies met the inclusion criteria. Methodological quality was evaluated using AMSTAR 2. Disagreements were resolved via consensus. Data analysis utilized a random-effects model in R software to estimate incidence rates of selected adverse events. After removing 1,198 duplicates and screening out irrelevant articles from a total of 2,591, we included 42 studies. Adverse reactions to vaccinations include myocarditis, thrombosis, skin reactions, GBS, etc. thrombosis and myocarditis are the most dangerous diseases associated with vaccination. Myocarditis occurred in 6% of Vector vaccine recipients, compared to 61% of mRNA vaccine recipients. Thrombosis was more common after Vector vaccination (91%) than after mRNA vaccination (9%). Furthermore, eight studies conducted anti-PF4 antibody tests and yielded a positivity rate of 67%. Meta-analysis showed that among all patients with Vaccine-induced Thrombotic Thrombocytopenia, cerebral venous sinus thrombosis occurred in 66%, and intracranial hemorrhage occurred in 43%. The rates of deep vein thrombosis and pulmonary thromboembolism in vaccinated patients were 13% and 23%, respectively, with a pooled case fatality rate of 30%. The results of this overview indicate the majority of adverse reactions are self-limiting and require minimal intervention, while rare occurrences such as myocarditis and thrombosis pose a potentially fatal threat.

Importance Alopecia areata (AA) is a common chronic tissue-specific autoimmune disease. Several studies have reported outcomes of Janus kinase (JAK) inhibitors for treating AA, but limited evidence has emerged. Objective To evaluate the effectiveness and safety associated with JAK inhibitors for AA. Data Sources MEDLINE, Embase, and CENTRAL (Cochrane Central Register of Controlled Trials) were searched from inception until August 2022. Study Selection Only randomized clinical trials (RCTs) were included. Pairs of reviewers independently and in duplicate selected the studies. Data Extraction and Synthesis Hartung-Knapp-Sidik-Jonkman random-effects models were used for meta-analysis. Certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach. This study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Main Outcomes and Measures The primary outcomes of interest were (1) proportion of patients who achieved 30%, 50%, and 90% improvement in Severity of Alopecia Tool (SALT) score from baseline, (2) change from baseline SALT score, and (3) treatment-related adverse event (AE). Results Seven RCTs with 1710 patients (1083 females [63.3%]; mean [SD] age range, 36.3 [10.4] to 69.7 [16.2] years) were eligible and included in the study. JAK inhibitors were associated with more patients achieving 50% improvement (odds ratio [OR], 5.28 [95% CI, 1.69-16.46]; GRADE assessment: low certainty) and 90% improvement (OR, 8.15 [95% CI, 4.42-15.03]; GRADE assessment: low certainty) in SALT score from baseline compared with placebo. JAK inhibitors were associated with more lowered SALT scores from the baseline compared with placebo (mean difference [MD], –34.52 [95% CI, −37.80 to −31.24]; GRADE assessment: moderate certainty), and JAK inhibitors were not associated with more treatment-related AEs (relative risk [RR], 1.25 [95% CI, 1.00-1.57]; GRADE assessment: high certainty) compared with placebo. High certainty of evidence showed that JAK inhibitors may not be associated with more severe AEs compared with placebo (RR, 0.77; 95% CI, 0.41-1.43). The subgroup analysis showed that oral JAK inhibitors were more efficient than placebo (change from baseline SALT scores: MD, –36.80; 95% CI, −39.57 to −34.02), and no difference was found between external JAK inhibitors and placebo (change from baseline SALT scores: MD, –0.40; 95% CI, −11.30 to 10.50). Conclusions and Relevance Results of this systematic review and meta-analysis suggest that JAK inhibitors, compared with placebo, were associated with hair regrowth and that the outcome of oral JAK inhibitors was better than the external route of administration. Although the safety and tolerability of JAK inhibitors were acceptable, longer RCTs are needed to further assess the effectiveness and safety of these treatments for AA.

Inconsistencies between a protocol and its umbrella review (UR) may mislead readers about the importance of findings or lead to false-positive results. Furthermore, not documenting and explaining inconsistencies in the UR could reduce its transparency. To our knowledge, no study has examined the methodological consistency of the protocols with their URs and assessed the transparency of the URs when generating evidence. This study aimed to investigate the inconsistency of protocols with their URs in the methodology and assess the transparency of the URs. We searched medical-related electronic databases from their inception to January 1, 2022. We investigated inconsistencies between protocols and their publications and transparencies in the search strategy, inclusion criteria, methods of screening and data extraction, quality assessment, and statistical analysis. We included 31 protocols and 35 publications. For the search strategy, 39 inconsistencies between the protocols and their publications were found in 26 of the 35 (74%) URs, and 16 of these inconsistencies were indicated and explained. There were 84 inconsistencies between the protocols and their URs regarding the inclusion criteria in 31 of the 35 (89%) URs, and 29 of the inconsistencies were indicated and explained. Deviations from their protocols were found in 12 of the 32 (38%) URs reporting the methods of screening, 14 of the 30 (47%) URs reporting the methods of data extraction, and 11 of the 32 (34%) URs reporting the methods for quality assessment. Of the 35 URs, 6 (17%) were inconsistent with their protocols in terms of the tools for quality assessment; one-half (3/6, 50%) of them indicated and explained the deviations. As for the statistical analysis, 31 of the 35 (89%) URs generated 61 inconsistencies between the publications and their protocols, and 16 inconsistencies were indicated and explained. There was a high prevalence of inconsistencies between protocols and publications of URs, and more than one-half of the inconsistencies were not indicated and explained in the publications. Therefore, how to promote the transparency of URs will be a major part of future work.

Visual impairment or even loss seriously affects quality of life. Benefited by the rapid development of sound/laser detection, Global Positioning System (GPS)/Beidou positioning, machine vision and other technologies, the quality of life of blind people is expected to be improved through visual substitution technology. The existing visual substitution devices still have limitations in terms of safety, robustness, and ease of operation. The remote companion system developed here fully utilizes multimodal navigation and remote communication technologies, and the positioning and interaction functions of commercial mobile phones. Together with the accumulated judgment of backend personnel, it can provide real-time, safe, and reliable navigation services for blind people, helping them complete daily activities such as independent travel, circulation, and shopping. The practical results show that the system not only has strong operability and is easy to use, but also can provide users with a strong sense of security and companionship, making it suitable for promotion. In the future, this system can also be promoted for other vulnerable groups such as the elderly.

Bitter gourd wilt, a severe vascular disease triggered by the soilborne pathogen Fusarium oxysporum f. sp. momordicae (FOM), markedly constrains bitter gourd yield. In this study, a novel strain BF19 of Brevibacillus brevis was isolated and identified, exhibiting strong antimicrobial activity against FOM through in vivo and in vitro experiments. To comprehensively assess the biocontrol potential of strain BF19, we conducted phenotypic, phylogenetic, and comparative genomics analyses. Phenotypic analysis revealed that BF19 exhibited 53.33% biocontrol efficacy and significantly increased the average plant height, root fresh weight, and dry weight. Whole-genome sequencing and comparative genomic analysis revealed numerous potential genes associated with biocontrol mechanisms in BF19. Importantly, the integration of metabolic cluster prediction with liquid chromatography‒tandem mass spectrometry (LC‒MS/MS) revealed the presence of a macrobrevin antibiotic, a product of polyketide synthases (PKSs), predominantly in BF19 fermentation products. The effectiveness of the Br. brevis strain BF19 and its crude extract against bitter gourd wilt has also been confirmed. This study provides a genetic framework for future investigations on PKSs and establishes a scientific basis for optimizing field applications of microbial biopesticides derived from Br. brevis BF19.

Purpose We analyzed clinical features and the representative HE-stained pathologic images to predict 5-year overall survival via the deep-learning approach in cervical cancer patients in order to assist oncologists in designing the optimal treatment strategies. Methods The research retrospectively collected 238 non-surgical cervical cancer patients treated with radiochemotherapy from 2014 to 2017. These patients were randomly divided into the training set ( n  = 165) and test set ( n  = 73). Then, we extract deep features after segmenting the HE-stained image into patches of size 224 × 224. A Lasso–Cox model was constructed with clinical data to predict 5-year OS. C-index evaluated this model performance with 95% CI, calibration curve, and ROC. Results Based on multivariate analysis, 2 of 11 clinical characteristics (C-index 0.68) and 2 of 2048 pathomic features (C-index 0.74) and clinical–pathomic model (C-index 0.83) of nomograms predict 5-year survival in the training set, respectively. In test set, compared with the pathomic and clinical characteristics used alone, the clinical–pathomic model had an AUC of 0.750 (95% CI 0.540–0.959), the clinical predictor model had an AUC of 0.729 (95% CI 0.551–0.909), and the pathomic model AUC was 0.703 (95% CI 0.487–0.919). Based on appropriate nomogram scores, we divided patients into high-risk and low-risk groups, and Kaplan–Meier survival probability curves for both groups showed statistical differences. Conclusion We built a clinical–pathomic model to predict 5-year OS in non-surgical cervical cancer patients, which may be a promising method to improve the precision of personalized therapy.

Coronavirus disease 2019 (COVID-19) pandemic has led to a rare reduction in human activities. In such a background, data from ground-based environmental stations, satellites, and reanalysis materials are utilized to conduct a comprehensive analysis of the global air quality changes during the COVID-19 outbreak. The results showed that under the impact of the COVID-19 outbreak, a significant decrease in particulate matter (PM x ) and nitrogen dioxide (NO 2 ) occurred in more than 40% of the world’s land area, with NO 2 (PM x ) decreasing by ∼30% (∼20%). The mobility, meteorological factors, and the response speed to COVID-19 outbreaks were examined. It was further found that in quick-response cities, lockdowns produced a sharp decline in mobility and had a dominant impact on air quality. In contrast, in slow-response cities, mobility dropped gradually since the confirmation of the first COVID-19 case (FCC) and he impact of the FCC, lockdowns, and meteorological factors were comparable.

Recognizing the inconvenience of magnetic resonance imaging (MRI) in evaluating the ocular morphology, this study developed a three-dimensional virtual whole eye model (CET-1) using ultra-widefield swept-source optical coherence tomography. The CET-1 were validated with MRI models in 80 eyes from 40 individuals with different extent of myopia. The result showed these two models have high consistency across different axial lengths (22.19 to 32.56 mm) -calculated as the mean point-to-surface distance, measuring 0.0183 ± 0.0025 normalized unit (439.57 ± 59.87 μm). Compared to the normal group, both of the posterior segment Gaussian curvature and anterior segment parameters demonstrated a significant change in myopic groups (P < 0.05). The CET-1 model provides a simple and effective tool that enables the establishment of a digital twin ocular model, facilitating the monitoring and quantitative analysis of myopia development and progression. Thus, supports optimized treatment strategies and contributes to the advancement of personalized medicine.